X4 Pharmaceuticals Financials - Benzinga

X4 Pharmaceuticals Inc

XFORNASDAQ

Trade with Public

Trade with Public

$3.46

0.061.76%

Últ. Act.: Sep 11, 3:41 PM

Panorámica general Noticias Previsión de beneficios Eventos Precios objetivoFinanzasSentimiento Propiedad Comparar Opciones Informe de acciones

X4 Pharmaceuticals Financials

X4 Pharmaceuticals (XFOR) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
X4 Pharmaceuticals Q2 EPS $(0.13) Beats $(0.18) Estimate, Sales $8.806M Beat $2.420M Estimate

X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.18) by 27.78 percent. This is a 96.25 percent increase over losses of $(3.47) per share

Benzinga Newsdesk

Earnings Scheduled For May 6, 2026

Benzinga Insights

PRO
X4 Pharmaceuticals Q1 EPS $(0.16) Beats $(0.20) Estimate, Sales $2.708M Miss $3.200M Estimate

X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.20) by 20 percent. This is a 500 percent decrease over earnings of $0.04 per share from the

Benzinga Newsdesk

PRO
X4 Pharmaceuticals Q4 EPS $(0.22) Beats $(0.38) Estimate, Sales $2.568M Beat $1.733M Estimate

X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.38) by 42.11 percent. This is a 96.26 percent increase over losses of $(5.89) per share

Benzinga Newsdesk

PRO
X4 Pharmaceuticals Q3 EPS $(0.69) Beats $(0.82) Estimate, Sales $1.765M Miss $1.901M Estimate

X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $(0.82) by 15.85 percent. This is a 87.41 percent increase over losses of $(5.48) per share

Benzinga Newsdesk

PRO
X4 Pharmaceuticals Q1 EPS $0.04 Beats $(4.44) Estimate, Sales $28.80M

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved